Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 4/20 | 0.57 |
| ▸ | THRA | P10827 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
| ▸ | RBP4 | P02753 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 6/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2777981 | 0.87 | PTGDR (0.53) | PTGDRRBP4FFAR4FFAR1 | |
| SCHEMBL3405256 | 0.83 | THRA (0.56) | PTGDRTHRATHRBFFAR4 | |
| SCHEMBL27724079 | 0.81 | PTGDR (0.48) | PTGDRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24180131 | 0.80 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3812430 | 0.79 | THRA (0.53) | PTGDRTHRATHRBPTGDR2RBP4 | |
| SCHEMBL32689796 | 0.78 | PTGDR (0.59) | PTGDRPTGDR2RBP4FFAR4FFAR1 | |
| SCHEMBL20472386 | 0.77 | CSNK2A1 (0.51) | PDE4A | |
| SCHEMBL29786553 | 0.77 | CSNK2A1 (0.51) | PDE4A | |
| SCHEMBL13679006 | 0.75 | PTGDR (0.46) | PTGDRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6063960 | 0.75 | THRA (0.50) | THRATHRBPTGDR2FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881958-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-7485752-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2009-02-03 | — | — | US | disclosed |
| CN-101171231-A | Diacylglycerol acyltransferase inhibitors | HOFFMANN LA ROCHE (CH) | 2008-04-30 | — | — | CN | disclosed |
| US-20060258740-A1 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258740-A1 | Diacylglycerol acyltransferase inhibitors | DGAT2, DGAT1, LCAT | PTGDR 635/4885THRA 2002/4885THRB 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.